These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29204973)

  • 1. External Validation of a Tool Predicting 7-Year Risk of Developing Cardiovascular Disease, Type 2 Diabetes or Chronic Kidney Disease.
    Rauh SP; Rutters F; van der Heijden AAWA; Luimes T; Alssema M; Heymans MW; Magliano DJ; Shaw JE; Beulens JW; Dekker JM
    J Gen Intern Med; 2018 Feb; 33(2):182-188. PubMed ID: 29204973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One risk assessment tool for cardiovascular disease, type 2 diabetes, and chronic kidney disease.
    Alssema M; Newson RS; Bakker SJ; Stehouwer CD; Heymans MW; Nijpels G; Hillege HL; Hofman A; Witteman JC; Gansevoort RT; Dekker JM
    Diabetes Care; 2012 Apr; 35(4):741-8. PubMed ID: 22338109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of the European risk assessment tool for chronic cardio-metabolic disorders in a Middle Eastern population.
    Asgari S; Moosaie F; Khalili D; Azizi F; Hadaegh F
    J Transl Med; 2020 Jul; 18(1):267. PubMed ID: 32615996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures.
    Chen L; Magliano DJ; Balkau B; Colagiuri S; Zimmet PZ; Tonkin AM; Mitchell P; Phillips PJ; Shaw JE
    Med J Aust; 2010 Feb; 192(4):197-202. PubMed ID: 20170456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of prediction models for nephropathy in people with type 2 diabetes: systematic review and external validation study.
    Slieker RC; van der Heijden AAWA; Siddiqui MK; Langendoen-Gort M; Nijpels G; Herings R; Feenstra TL; Moons KGM; Bell S; Elders PJ; 't Hart LM; Beulens JWJ
    BMJ; 2021 Sep; 374():n2134. PubMed ID: 34583929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model.
    Helmink MAG; Peters SAE; Westerink J; Harris K; Tillmann T; Woodward M; van Sloten TT; van der Meer MG; Teraa M; Dorresteijn JAN; Ruigrok YM; Visseren FLJ; Hageman SHJ;
    Eur J Prev Cardiol; 2024 Oct; 31(14):1671-1678. PubMed ID: 38584392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus.
    van der Leeuw J; van Dieren S; Beulens JW; Boeing H; Spijkerman AM; van der Graaf Y; van der A DL; Nöthlings U; Visseren FL; Rutten GE; Moons KG; van der Schouw YT; Peelen LM
    Heart; 2015 Feb; 101(3):222-9. PubMed ID: 25256148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of a Prediction Model for Future Estimated Glomerular Filtration Rate in People With Type 2 Diabetes and Chronic Kidney Disease.
    Gregorich M; Kammer M; Heinzel A; Böger C; Eckardt KU; Heerspink HL; Jung B; Mayer G; Meiselbach H; Schmid M; Schultheiss UT; Heinze G; Oberbauer R;
    JAMA Netw Open; 2023 Apr; 6(4):e231870. PubMed ID: 37017968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External validation of prognostic models for chronic kidney disease among type 2 diabetes.
    Saputro SA; Pattanateepapon A; Pattanaprateep O; Aekplakorn W; McKay GJ; Attia J; Thakkinstian A
    J Nephrol; 2022 Jul; 35(6):1637-1653. PubMed ID: 34997924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Applications of the NDR and DIAL models for risk prediction on cardiovascular disease in patients with type 2 diabetes in Ningbo].
    Li QQ; Liang JY; Wang JM; Shen P; Sun YX; Chen Q; Wu JG; Lu P; Zhang JY; Lin HB; Tang X; Gao P
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Jun; 43(6):945-952. PubMed ID: 35725354
    [No Abstract]   [Full Text] [Related]  

  • 11. External validation of a cardiovascular risk model for Omani patients with type 2 diabetes mellitus: a retrospective cohort study.
    Al Oraimi F; Al Rawahi A; Al Harrasi A; Albusafi S; Al-Manji LM; Alrawahi AH; Al Salmani AA
    BMJ Open; 2023 Nov; 13(11):e071369. PubMed ID: 37968004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: A nationwide cohort and modeling study.
    Wilkinson L; Yi N; Mehta T; Judd S; Garvey WT
    PLoS Med; 2020 Aug; 17(8):e1003232. PubMed ID: 32764746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Prediction Models for Atherosclerotic Cardiovascular Disease in Patients with Chronic Kidney Disease: The CRIC Study.
    Bundy JD; Rahman M; Matsushita K; Jaeger BC; Cohen JB; Chen J; Deo R; Dobre MA; Feldman HI; Flack J; Kallem RR; Lash JP; Seliger S; Shafi T; Weiner SJ; Wolf M; Yang W; Allen NB; Bansal N; He J;
    J Am Soc Nephrol; 2022 Mar; 33(3):601-611. PubMed ID: 35145041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study.
    Hippisley-Cox J; Coupland C
    BMJ; 2017 Nov; 359():j5019. PubMed ID: 29158232
    [No Abstract]   [Full Text] [Related]  

  • 15. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
    Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
    JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recalibration and validation of the SCORE risk chart in the Australian population: the AusSCORE chart.
    Chen L; Tonkin AM; Moon L; Mitchell P; Dobson A; Giles G; Hobbs M; Phillips PJ; Shaw JE; Simmons D; Simons LA; Fitzgerald AP; De Backer G; De Bacquer D
    Eur J Cardiovasc Prev Rehabil; 2009 Oct; 16(5):562-70. PubMed ID: 19741542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk prediction models for incident type 2 diabetes in Chinese people with intermediate hyperglycemia: a systematic literature review and external validation study.
    Xu S; Coleman RL; Wan Q; Gu Y; Meng G; Song K; Shi Z; Xie Q; Tuomilehto J; Holman RR; Niu K; Tong N
    Cardiovasc Diabetol; 2022 Sep; 21(1):182. PubMed ID: 36100925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of clinical prediction models for renal and cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease using time-varying predictors.
    Ye W; Ding X; Putnam N; Farej R; Singh R; Wang D; Kuo S; Kong SX; Elliott JC; Lott J; Herman WH
    J Diabetes Complications; 2022 May; 36(5):108180. PubMed ID: 35339377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prediction model on incident ESKD among individuals with T2D and CKD.
    Lin Y; Shao H; Fonseca V; Anderson AH; Batuman V; Shi L
    J Diabetes Complications; 2023 Apr; 37(4):108450. PubMed ID: 36871314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk prediction in a population with the metabolic syndrome: Framingham vs. UKPDS algorithms.
    Zomer E; Liew D; Owen A; Magliano DJ; Ademi Z; Reid CM
    Eur J Prev Cardiol; 2014 Mar; 21(3):384-90. PubMed ID: 22588087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.